Ted White
Equibles does not estimate personal net worth.
About Ted White
Earlier roles on record: CEO at Verrica Pharmaceuticals Inc. (VRCA) until November 5, 2024. Verrica Pharmaceuticals Inc. reported in an 8-K filed November 4, 2024 that Ted White resigned as member of the Company's Board of Directors, effective November 5, 2024. Verrica Pharmaceuticals Inc. reported in an 8-K filed November 4, 2024 that Ted White resigned as President and Chief Executive Officer, effective November 5, 2024. The proxy statement of Verrica Pharmaceuticals Inc. reports total compensation of $2,594,832 for Ted White in fiscal 2024, including a base salary of $527,618. Disclosed compensation is on record for 5 fiscal years. Ted White has spoken on 4 earnings calls across 1 company, most recently for Verrica Pharmaceuticals Inc. on August 14, 2024. The companies whose calls Ted White spoke on are classified in the Healthcare sector.
“On November 1, 2024, Ted White notified the Company that he will resign from his positions as the Company's President and Chief Executive Officer and as a member of the Company's Board of Directors (the "Board") effective as of November 5, 2024 (the "Effective Date") (such resignation, the "White Resignation").”
“On November 1, 2024, Ted White notified the Company that he will resign from his positions as the Company's President and Chief Executive Officer and as a member of the Company's Board of Directors (the "Board") effective as of November 5, 2024 (the "Effective Date") (such resignation, the "White Resignation").”
Ted White on recent calls
“I appreciate you joining us for the second quarter 2024 earnings call. I'm pleased to report that we continue to make progress across our business, including with the commercial launch of YCANTH and the exciting data being generated from our development stage pipeline.”
“Thank you, Chris, and good morning, everyone, and thank you for joining us for the first quarter 2024 earnings call. I'd like to begin today's call by discussing the progress we've made with the launch of YCANTH, which remains the top priority for the organization.”
“Thank you, Kevin and good morning, everyone, and thank you for joining us for our fourth quarter and year end 2023 earnings call. I'd like to begin today's call by providing an update on Verrica's commercial launch since our last quarterly earnings call back in November.”
“Thank you, Kevin, and good morning, everyone, and thank you for joining us for our third quarter 2023 corporate update and earnings conference call. I'd like to begin today's call by providing a general update on the progress we've made since the second quarter.”
Affiliation history
-
Start not stated–2024-11-05
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Verrica Pharmaceuticals Inc. (VRCA) | Former President and Chief Executive Officer | $527,618 | $2,594,832 |
| 2023 | Verrica Pharmaceuticals Inc. (VRCA) | Former President and Chief Executive Officer | $600,600 | $3,504,647 |
| 2022 | Verrica Pharmaceuticals Inc. (VRCA) | President, Chief Executive Officer and Director | $572,000 | $1,935,834 |
| 2020 | Verrica Pharmaceuticals Inc. (VRCA) | President, Chief Executive Officer and Director | $485,000 | $1,706,704 |
| 2019 | Verrica Pharmaceuticals Inc. (VRCA) | President, Chief Executive Officer and Director | $433,333 | $1,441,189 |